Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mycosis Fungoides: early-phase trial registry
13 of 20 indexed Mycosis Fungoides trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 13 currently recruiting · #848 of 28,707 conditions by registered trial count
Mycosis Fungoides: 20 US clinical trials tracked, 13 recruiting.
Mycosis Fungoides is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition mycosis-fungoides
OPEN 13 | RECR 65% | LATE 2 | EARLY 14 | RANK #848 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Focal Segmental Glomerulosclerosis (65% recruiting · 20 trials)
Mycosis Fungoides lists 13 open slots (65% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mycosis Fungoides on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mycosis Fungoides is recruiting above its size-band peers.
13 of 20 indexed trials (65%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mycosis Fungoides research.
M.D. Anderson Cancer Center accounts for 4 of 20 trials (20%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Mycosis Fungoides trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 20 trials that report a genuine target (sentinel values excluded). 16 of those (80%) plan for fewer than 100 participants.
-
Mycosis Fungoides research is mostly interventional.
16 interventional and 4 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Stanford University
NCT02848274
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
University of Pittsburgh
NCT00177268
Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
M.D. Anderson Cancer Center
NCT06207812
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Soligenix
NCT06470451
Photopheresis in Early-stage Mycosis Fungoides
Columbia University
NCT05680558
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07055477
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center
NCT03587844
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
NCT03398161
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
NCT04256018
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
NCT05357794
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Northwestern University
NCT05838599
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
NCT06508463
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
NCT05414500
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
NCT01352520
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT03602157
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Washington University School of Medicine
NCT05944562
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center
NCT04960618
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai
NCT00050999
Effect of Denileukin Diftitox on Immune System in CTCL Patients
University of Pittsburgh
NCT00254332
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
NCT00047060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 7 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mycosis Fungoides records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mycosis Fungoides trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mycosis Fungoides page
20 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Mycosis Fungoides trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Mycosis Fungoides trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mycosis Fungoides condition card totals 20 registered trials; most-linked intervention Mogamulizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.